"Strains Available Anywhere"... Daewoong Submits Additional Data to ITC

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 25th that it purchased the botulinum strain (Hall A Hyper) in the United States and submitted it to the U.S. International Trade Commission (ITC). This was to emphasize that the Hall A Hyper strain, which Medytox claims as a trade secret, has been and still is easily obtainable anywhere in the world.

On the same day, Daewoong Pharmaceutical additionally submitted a statement to the ITC stating that "contrary to Medytox's claims, the botulinum strain is easily obtainable."

Earlier in July, the ITC preliminarily ruled that "Daewoong Pharmaceutical misappropriated Medytox's trade secrets, including the botulinum strain and manufacturing process." However, on the 21st, the ITC accepted Daewoong Pharmaceutical's objection and decided to reexamine part of the preliminary ruling.

A Daewoong Pharmaceutical official said, "After the ITC lawsuit, several companies and institutions informed Daewoong Pharmaceutical that the botulinum strain could be transferred," adding, "We selected and purchased one of them." They further claimed, "Through the submission of the purchase of a new strain, we have proven that the trade secret nature of the strain is based on flawed logic."

Regarding the acceptance of Daewoong Pharmaceutical's objection, Daewoong Pharmaceutical expects to overturn the preliminary ruling and achieve a final victory, while Medytox maintains that this is just a routine procedure.

The ITC will reexamine the main issues and deliver a final ruling on November 6 (local time).

This content was produced with the assistance of AI translation services.